Enfermedades alérgicas

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. Collection of Tissue and Blood in Patients with Allergic and Immunologic Disorders

   Scottsdale/Phoenix, Ariz.

   Allergic and immunologic disorders are very common but some are very poorly understood. Numerous studies of the epidemiology, characteristics, diagnosis and treatment of these disorders are urgently needed to identify and optimally treat affected patients. Though numerous challenges impact the progress of research in this area, specimens are needed to test new hypotheses and methodologies.  We aim to create a registry and biorepository of tissue and fluid specimens for future studies.

2. Participation in a Research Registry for Immune Disorders

   Rochester, Minn.

   The purpose of this study is to build a National Registry of individuals with one of the group of primary immune deficiency diseases. A "Registry" is a list of basic information about people who have a certain disease or condition in common. These immune deficiency diseases are thought to be rare and include: Severe combined immunodeficiency (SCID), leukocyte adhesion deficiency (LAD), X-linked Agammaglobulinemia (XLA), common variable immune deficiency (CVID), DiGeorge syndrome (DGS), Hyper IgM syndrome (HIGM), Wiskott Aldrich syndrome (WAS) and chronic granulomatous disease (CGD). We would like to contribute data on a number of subjects with these relatively rare diseases to this National Registry Data Base. The information will be age, sex, race or ethnic group, immunologic lab tests that were used to diagnose the condition, what complications may have occurred since the condition started, lung disease, blood changes, etc. and the results of various treatments used. The goal is to discover basic outcome data, ethnic, racial characteristics, kind of complications and useful treatments. You will not be contacted by anyone unless you authorize it. If a new study about you (or your child’s) immune defect comes up, your doctor will be notified, who can then share this with you to find out if you are interested in participating or not. Alternatively you may elect to be contacted directly by the Registry to determine your interest in participation.

3. Study to Analyze the Metabolic Environment in Preventing Atopic Dermatitis

   Rochester, Minn.

   The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as compared to age/sex and diet matched control children without atopic dermatitis, and to apply mass-spectrometry-based metabolomic approach to analyzing fecal, nasal, oral and skin samples from cases, in order to characterize their biochemical metabolic profiles by comparison with those of their controls.

4. C. Albicans during Early Life Predisposes Individuals to Atopy

   Rochester, Minn.

   The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis.

   We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations.

    

5. A Study of Biomarkers for the Diagnosis of Mastocytosis

   Rochester, Minn.

   The purpose of this study is to identify biomarkers that can show differences in mast cell disease (Mastocytosis) status and activity for help with diagnosis and prognosis.

6. Mayo Clinic Drug Allergy Repository

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

   The purpose of this study is to build a Mayo Clinic registry of data and biobank from subjects with drug allergy. The data collected will include demographic, diagnostic, and health data on a large group of patients to discover novel drug allergy diagnostic methods.

7. Evaluation of Immunophenotype Signatures in Hypereosinophilia-Associated Disorders

   Rochester, Minn.

   The purpose of this study is to characterize the immunophenotype of individuals with hypereosinophilia-associated cardiovascular, gastrointestinal, hematologic, and respiratory disorders.

8. Mayo Clinic Program for the Study of Mast Cell and Eosinophil Disorders Cell and Serum Bank

   Rochester, Minn.

   This study is being done to store blood cells, genetic material, blood serum and tissue biopsies so that they can be used in laboratory studies now and in the future to find causes of the rare disorder of mast cells and/or eosinophils and factors that may contribute to disease progression and treatment response.

9. Excretion of Mast Cell Mediators in Children with Allergic Disorders

   Rochester, Minn.

   The aim of this study is to examine the role of mast cell mediators in children with allergic disorders in a two part study. Part 1 of the study will prospectively obtain the values of mast cell mediators, including 2,3 dinor 11β-PGF2α, n-MH, and LTE4 in the urine of a healthy pediatric reference population. Part 2 of the study will prospectively evaluate the urine concentrations of mast cell mediators in a cohort of pediatric allergic disorder patients including asthma, allergic rhinoconjunctivitis, eczema, urticaria, systemic anaphylaxis, and mast cell disorders, as well as POTS (postural orthostatic tachycardia syndrome). Comparisons of these values in the disease cohort will be made utilizing the pediatric expected reference intervals established in Part 1. Further analysis will determine if one or several urine mast cell mediators are elevated in a particular allergic disorder.

10. Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of Sulfonamide Allergy

    Rochester, Minn.

    The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in hematologic malignancy, hematopoietic stem cell transplant, and solid organ transplant patients.    

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. Collection of Tissue and Blood in Patients with Allergic and Immunologic Disorders

   Scottsdale/Phoenix, Ariz.

   Allergic and immunologic disorders are very common but some are very poorly understood. Numerous studies of the epidemiology, characteristics, diagnosis and treatment of these disorders are urgently needed to identify and optimally treat affected patients. Though numerous challenges impact the progress of research in this area, specimens are needed to test new hypotheses and methodologies.  We aim to create a registry and biorepository of tissue and fluid specimens for future studies.

2. Participation in a Research Registry for Immune Disorders

   Rochester, Minn.

   The purpose of this study is to build a National Registry of individuals with one of the group of primary immune deficiency diseases. A "Registry" is a list of basic information about people who have a certain disease or condition in common. These immune deficiency diseases are thought to be rare and include: Severe combined immunodeficiency (SCID), leukocyte adhesion deficiency (LAD), X-linked Agammaglobulinemia (XLA), common variable immune deficiency (CVID), DiGeorge syndrome (DGS), Hyper IgM syndrome (HIGM), Wiskott Aldrich syndrome (WAS) and chronic granulomatous disease (CGD). We would like to contribute data on a number of subjects with these relatively rare diseases to this National Registry Data Base. The information will be age, sex, race or ethnic group, immunologic lab tests that were used to diagnose the condition, what complications may have occurred since the condition started, lung disease, blood changes, etc. and the results of various treatments used. The goal is to discover basic outcome data, ethnic, racial characteristics, kind of complications and useful treatments. You will not be contacted by anyone unless you authorize it. If a new study about you (or your child’s) immune defect comes up, your doctor will be notified, who can then share this with you to find out if you are interested in participating or not. Alternatively you may elect to be contacted directly by the Registry to determine your interest in participation.

3. Study to Analyze the Metabolic Environment in Preventing Atopic Dermatitis

   Rochester, Minn.

   The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as compared to age/sex and diet matched control children without atopic dermatitis, and to apply mass-spectrometry-based metabolomic approach to analyzing fecal, nasal, oral and skin samples from cases, in order to characterize their biochemical metabolic profiles by comparison with those of their controls.

4. C. Albicans during Early Life Predisposes Individuals to Atopy

   Rochester, Minn.

   The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis.

   We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations.

    

5. Mayo Clinic Drug Allergy Repository

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Eau Claire, Wis.

   The purpose of this study is to build a Mayo Clinic registry of data and biobank from subjects with drug allergy. The data collected will include demographic, diagnostic, and health data on a large group of patients to discover novel drug allergy diagnostic methods.

6. A Study of Biomarkers for the Diagnosis of Mastocytosis

   Rochester, Minn.

   The purpose of this study is to identify biomarkers that can show differences in mast cell disease (Mastocytosis) status and activity for help with diagnosis and prognosis.

7. Evaluation of Immunophenotype Signatures in Hypereosinophilia-Associated Disorders

   Rochester, Minn.

   The purpose of this study is to characterize the immunophenotype of individuals with hypereosinophilia-associated cardiovascular, gastrointestinal, hematologic, and respiratory disorders.

8. Mayo Clinic Program for the Study of Mast Cell and Eosinophil Disorders Cell and Serum Bank

   Rochester, Minn.

   This study is being done to store blood cells, genetic material, blood serum and tissue biopsies so that they can be used in laboratory studies now and in the future to find causes of the rare disorder of mast cells and/or eosinophils and factors that may contribute to disease progression and treatment response.

9. Excretion of Mast Cell Mediators in Children with Allergic Disorders

   Rochester, Minn.

   The aim of this study is to examine the role of mast cell mediators in children with allergic disorders in a two part study. Part 1 of the study will prospectively obtain the values of mast cell mediators, including 2,3 dinor 11β-PGF2α, n-MH, and LTE4 in the urine of a healthy pediatric reference population. Part 2 of the study will prospectively evaluate the urine concentrations of mast cell mediators in a cohort of pediatric allergic disorder patients including asthma, allergic rhinoconjunctivitis, eczema, urticaria, systemic anaphylaxis, and mast cell disorders, as well as POTS (postural orthostatic tachycardia syndrome). Comparisons of these values in the disease cohort will be made utilizing the pediatric expected reference intervals established in Part 1. Further analysis will determine if one or several urine mast cell mediators are elevated in a particular allergic disorder.

10. New Mast Cell Lines from Patients with Systemic Mastocytosis

    Rochester, Minn.

    The purpose of this study is to attempt to establish new mast cell lines from patients with systemic mastocytosis using peripheral blood and/or bone marrow.